Drug firm Granules India Ltd on Monday (November 2) reported a 39.2% year-on-year (YoY) increase in consolidated net profit to ₹182 crore for the second quarter, compared with ₹131 crore in the corresponding period last year.
Revenue from operations rose 20.3% to ₹1,560 crore from ₹1,297 crore a year ago.
Earnings before interest, taxes, depreciation and amortisation (EBITDA) increased 21.3% YoY to ₹337.4 crore, compared with ₹278.1 crore in the year-ago quarter. The EBITDA margin improved to 21.6% from 21.4% in the corresponding quarter last year.
ALSO READ | Granules India’s Gagillapur facility gets 11 observations in USFDA inspection
Granules India’s revenue from operations stood at ₹1,560 crore in Q2FY27, registering a 20% year-on-year (YoY) growth. North America accounted for 72% of the company’s revenue in Q2FY27, compared with 76% in Q2FY26, while Europe’s share increased to 16% from 12% during the same period.
Finished dosages (FD) contributed 73% of revenue from operations, followed by Active Pharmaceutical Ingredients (API) at 13%, Pharmaceutical Formulation Intermediates (PFI) at 10% and Peptides Contract Development and Manufacturing Organisation (CDMO) at 3%.
The company’s return on capital employed (ROCE) stood at 17.6% in Q2FY27, in line with FY26. Granules India closed the quarter with a net cash position of ₹828 crore, compared with net debt of ₹101.2 crore at the end of Q1FY27.
ALSO READ | Granules India Q1 Results: 22% revenue growth aids profit jump; Operating performance strong
Dr Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India Limited, said, “Our quarterly revenue has crossed ₹1,500 crore in Q2 FY27 with EBITDA of ₹338 crore, despite higher input and logistics costs from tensions in West Asia. Cost pressures will persist, and we are working with customers to manage them with a lag.
We filed two potential first-to-file ANDAs in H1, which makes it a total of three potential first-to-file ANDAs and continue to shift towards complex generics and peptide CDMO. With the balance warrant proceeds received, we hold net cash of ₹828 crore to invest in R&D, manufacturing and quality
We recently concluded a US FDA audit at the Gagillapur site. The inspection progressed constructively, and the observations are of a nature that we believe can be fully addressed through our responses and corrective and preventive actions, and we will continue to engage transparently with the agency.”
ALSO READ | Granules India Q4 Results: Stock at record high after strong operating performance; Profit up 32%
Shares of Granules India Ltd ended at ₹819.55, down by ₹20.00, or 2.38%, on the BSE.